LPL

1. LPL lowers the risk of chronic kidney disease in humans (OR 0.86 [95% CI 0.83 to 0.90]).

   Humansfor each 1-SD decrease in triglycerides

   The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study · American journal of kidney diseases : the official journal of the National Kidney Foundation · 22 Sep 2026

Chronic kidney disease →

1. LPL is associated with dyslipidemia in humans (P = 5.79 × 10-22).

   Humansmulti-trait analysis of lipid traits in African-ancestry populationsn = 34,039

   Pleiotropy and eQTL analysis identify shared genetic architecture of lipid traits in African-ancestry populations · Human molecular genetics · 11 Sep 2026

Dyslipidemia →

1. LPL is associated with plasma triglyceride in chylomicrons and extremely large VLDL particles in humans.

   Humansn = 373,882

   Genetic trans-effects link triglyceride-rich lipoproteins to blood pressure · bioRxiv · 8 Sep 2026 · Preprint

Plasma triglyceride in chylomicrons and extremely large VLDL particles →

1. LPL is associated with body mass index in humans.

   Humansn = 373,882

   Genetic trans-effects link triglyceride-rich lipoproteins to blood pressure · bioRxiv · 8 Sep 2026 · Preprint

1. LPL is associated with mean arterial pressure in humans.

   Humansn = 373,882

   Genetic trans-effects link triglyceride-rich lipoproteins to blood pressure · bioRxiv · 8 Sep 2026 · Preprint